Lorcaserin (APD356), a Selective 5‐HT 2C Agonist, Reduces Body Weight in Obese Men and Women

Lorcaserin (APD356), a Selective 5‐HT 2C Agonist, Reduces Body Weight in Obese Men and Women Lorcaserin (APD356) is a potent, selective 5‐HT2C agonist with ∼15‐fold and 100‐fold selectivity vs. 5‐HT2A and 5‐HT2B receptors, respectively. This study evaluated the safety and efficacy of lorcaserin for weight reduction in obese patients during a 12‐week period. The randomized, double‐blind, placebo‐controlled, parallel‐arm study enrolled 469 men and women between ages 18 and 65 and with BMI 30–45 kg/m2. Patients received placebo, lorcaserin 10 mg q.d., lorcaserin 15 mg q.d., or lorcaserin 10 mg b.i.d. for 12 weeks, and were counseled to maintain their usual diet and activity. The primary end point was change in weight from baseline to day 85 by completer analysis. Safety analyses included echocardiograms at Screening and day 85/study exit. Lorcaserin was associated with progressive weight loss of 1.8 kg, 2.6 kg, and 3.6 kg at 10 mg q.d., 15 mg q.d., and 10 mg b.i.d., respectively, compared to placebo weight loss of 0.3 kg (P < 0.001 for each group). Similar results were seen by intent‐to‐treat last observation‐carried forward (ITT‐LOCF) analysis. The proportions of completers achieving ≥5% of initial body weight were 12.8, 19.5, 31.2, and 2.3% in the 10 mg q.d., 15 mg q.d., 10 mg b.i.d., and placebo groups, respectively. The most frequent adverse events (AEs) were transient headache, nausea, and dizziness. Echocardiograms showed no apparent drug‐related effects on heart valves or pulmonary artery pressure (PAP). Lorcaserin was well tolerated and efficacious for weight reduction in this 12‐week study. Longer‐term trials employing behavior modification will be needed to more fully assess its safety and efficacy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Obesity Wiley

Lorcaserin (APD356), a Selective 5‐HT 2C Agonist, Reduces Body Weight in Obese Men and Women

Loading next page...
 
/lp/wiley/lorcaserin-apd356-a-selective-5-ht-2c-agonist-reduces-body-weight-in-OHAIJragSN
Publisher
Wiley
Copyright
2009 North American Association for the Study of Obesity (NAASO)
ISSN
1930-7381
eISSN
1930-739X
DOI
10.1038/oby.2008.537
Publisher site
See Article on Publisher Site

Abstract

Lorcaserin (APD356) is a potent, selective 5‐HT2C agonist with ∼15‐fold and 100‐fold selectivity vs. 5‐HT2A and 5‐HT2B receptors, respectively. This study evaluated the safety and efficacy of lorcaserin for weight reduction in obese patients during a 12‐week period. The randomized, double‐blind, placebo‐controlled, parallel‐arm study enrolled 469 men and women between ages 18 and 65 and with BMI 30–45 kg/m2. Patients received placebo, lorcaserin 10 mg q.d., lorcaserin 15 mg q.d., or lorcaserin 10 mg b.i.d. for 12 weeks, and were counseled to maintain their usual diet and activity. The primary end point was change in weight from baseline to day 85 by completer analysis. Safety analyses included echocardiograms at Screening and day 85/study exit. Lorcaserin was associated with progressive weight loss of 1.8 kg, 2.6 kg, and 3.6 kg at 10 mg q.d., 15 mg q.d., and 10 mg b.i.d., respectively, compared to placebo weight loss of 0.3 kg (P < 0.001 for each group). Similar results were seen by intent‐to‐treat last observation‐carried forward (ITT‐LOCF) analysis. The proportions of completers achieving ≥5% of initial body weight were 12.8, 19.5, 31.2, and 2.3% in the 10 mg q.d., 15 mg q.d., 10 mg b.i.d., and placebo groups, respectively. The most frequent adverse events (AEs) were transient headache, nausea, and dizziness. Echocardiograms showed no apparent drug‐related effects on heart valves or pulmonary artery pressure (PAP). Lorcaserin was well tolerated and efficacious for weight reduction in this 12‐week study. Longer‐term trials employing behavior modification will be needed to more fully assess its safety and efficacy.

Journal

ObesityWiley

Published: Mar 1, 2009

References

  • Early decreases in plasma lipid transfer proteins during weight reduction
    Tzotzas, Tzotzas; Dumont, Dumont; Triantos, Triantos
  • A review of central 5‐HT receptors and their function
    Barnes, Barnes; Sharp, Sharp
  • The role of serotonin in antipsychotic drug action
    Meltzer, Meltzer
  • Effect of fenfluramine‐derivative diet pills on cardiac valves: a meta‐analysis of observational studies
    Sachdev, Sachdev; Miller, Miller; Ryan, Ryan; Jollis, Jollis

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off